Idexx Laboratories IDXX Total CAG Diagnostics recurring revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Idexx Laboratories in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Idexx Laboratories's total cag diagnostics recurring revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Idexx Laboratories's total CAG diagnostics recurring revenue — total revenue?
- Idexx Laboratories (IDXX) reported total CAG diagnostics recurring revenue — total revenue of $920.31M in Q1 2026.
- How has Idexx Laboratories's total CAG diagnostics recurring revenue — total revenue changed year-over-year?
- Idexx Laboratories's total CAG diagnostics recurring revenue — total revenue increased by 14.1% year-over-year, from $806.27M to $920.31M.
- What is the long-term trend for Idexx Laboratories's total CAG diagnostics recurring revenue — total revenue?
- Over 4 years (2021 to 2025), Idexx Laboratories's total CAG diagnostics recurring revenue — total revenue has grown at a 7.7% compound annual growth rate (CAGR), from $2.53B to $3.41B.
- What does total CAG diagnostics recurring revenue — total revenue mean?
- This metric represents the proportion of total consolidated revenue derived from recurring diagnostic product and service offerings within the Companion Animal Group segment. It captures the stability of the revenue stream generated by consumable test kits, reference laboratory services, and software subscriptions that veterinarians rely on for daily practice operations. By isolating this recurring component, investors can assess the company's ability to generate predictable, long-term cash flows from its installed base of diagnostic equipment.